Document Classification

Section Type: RESULTS

Text: At the end of the study, there were no differences in mortality (17. 8 % vs. 22. 9 %, P = 0. 53), number of exacerbations (33 vs. 41, P = 0. 40), pulse oximetry (median 91. 71 % vs. 92. 46 %, P = 0. 18), FEV1 (median 51. 31 % vs. 47. 14 %, P = 0. 30), health-related quality of life (median 8. 63 vs. 10. 75, P = 0. 94) and infection-free interval (median 112 vs. 101 days, P = 0. 72), for the levofloxacin and standard therapy, respectively.